Actively Recruiting
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
Led by Sahlgrenska University Hospital · Updated on 2026-03-27
160
Participants Needed
1
Research Sites
314 weeks
Total Duration
On this page
Sponsors
S
Sahlgrenska University Hospital
Lead Sponsor
K
Karolinska University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
CONDITIONS
Official Title
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)
- Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)
- Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)
You will not qualify if you...
- Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
- Previous RPLND
- Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sahlgrenska University Hospital
Gothenburg, Göteborg, Sweden, 413 45
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here